Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Milsaperidone · Bysanti, VHX-896

Small molecule · Antagonist of dopamine D2 receptor (DRD2) and serotonin 5-HT2 receptor (HTR2A) · developed by Vanda Pharms

Approved FDA, Feb 2026

VNDA Developer

2 Registered trials

What is Milsaperidone?

Milsaperidone is an atypical antipsychotic small molecule that acts as a dopamine D2 and serotonin 5-HT2 receptor antagonist. Milsaperidone rapidly interconverts with iloperidone in vivo.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Bysanti, VHX-896
Drug type: Small molecule
Targets: dopamine D2 receptor (DRD2), serotonin 5-HT2 receptor (HTR2A)
Mechanism: Antagonist of dopamine D2 receptor (DRD2) and serotonin 5-HT2 receptor (HTR2A)
Therapy area: Psychiatry
Developer: Vanda Pharms Inc (VNDA)
FDA status: Approved as Bysanti (February 20, 2026), NDA220358 · FDA label
UNII: 7SV1ZOG031

✅ FDA-approved uses

Treatment of schizophrenia in adults
Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults

From the indications section of the FDA label (version of Feb 27, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06830044	Phase 3	Major Depressive Disorder (MDD)	Recruiting	VNDA
NCT06803290	Phase 1	Healthy	Completed	VNDA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Major Depressive Disorder (MDD)Healthy

Other drugs acting on DRD2 / HTR2A

Aripiprazole Lauroxil FDA approved Asenapine FDA approved Iloperidone FDA approved Pimavanserin FDA approved ONC206 Phase 2 Psilocybin Phase 3

More from Vanda Pharms

Iloperidone FDA approved Ponesimod FDA approved Tasimelteon FDA approved Tradipitant FDA approved Trichostatin A Phase 2 VCA-894A Phase 1/2 VQW-765 Phase 3 VSJ-110 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the VNDA page.

Follow VNDA, the company behind Milsaperidone

See VNDA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VNDA catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z